Literature DB >> 24697554

Morphine-induced internalization of the L83I mutant of the rat μ-opioid receptor.

A E Cooke1, S Oldfield, C Krasel, S J Mundell, G Henderson, E Kelly.   

Abstract

BACKGROUND AND
PURPOSE: Naturally occurring single-nucleotide polymorphisms (SNPs) within GPCRs can result in alterations in various pharmacological parameters. Understanding the regulation and function of endocytic trafficking of the μ-opioid receptor (MOP receptor) is of great importance given its implication in the development of opioid tolerance. This study has compared the agonist-dependent trafficking and signalling of L83I, the rat orthologue of a naturally occurring variant of the MOP receptor. EXPERIMENTAL APPROACH: Cell surface elisa, confocal microscopy and immunoprecipitation assays were used to characterize the trafficking properties of the MOP-L83I variant in comparison with the wild-type receptor in HEK 293 cells. Functional assays were used to compare the ability of the L83I variant to signal to several downstream pathways. KEY
RESULTS: Morphine-induced internalization of the L83I MOP receptor was markedly increased in comparison with the wild-type receptor. The altered trafficking of this variant was found to be specific to morphine and was both G-protein receptor kinase- and dynamin-dependent. The enhanced internalization of L83I variant in response to morphine was not due to increased phosphorylation of serine 375, arrestin association or an increased ability to signal. CONCLUSIONS AND IMPLICATIONS: These results suggest that morphine promotes a specific conformation of the L83I variant that makes it more liable to internalize in response to morphine, unlike the wild-type receptor that undergoes significantly less morphine-stimulated internalization, providing an example of a ligand-selective biased receptor. The presence of this SNP within an individual may consequently affect the development of tolerance and analgesic responses. LINKED ARTICLES: This article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-2.
© 2014 The British Pharmacological Society.

Entities:  

Keywords:  G-protein coupled receptor; morphine; receptor internalization; μ-opioid receptor

Mesh:

Substances:

Year:  2014        PMID: 24697554      PMCID: PMC4292971          DOI: 10.1111/bph.12709

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  61 in total

Review 1.  Opioid receptor and peptide gene polymorphisms: potential implications for addictions.

Authors:  K S LaForge; V Yuferov; M J Kreek
Journal:  Eur J Pharmacol       Date:  2000-12-27       Impact factor: 4.432

2.  Cellular morphine tolerance produced by βarrestin-2-dependent impairment of μ-opioid receptor resensitization.

Authors:  Vu C Dang; Billy Chieng; Yael Azriel; MacDonald J Christie
Journal:  J Neurosci       Date:  2011-05-11       Impact factor: 6.167

3.  A single residue in the S6 transmembrane domain governs the differential flecainide sensitivity of voltage-gated potassium channels.

Authors:  Daniel Herrera; Aida Mamarbachi; Manuel Simoes; Lucie Parent; Rémy Sauvé; Zhiguo Wang; Stanley Nattel
Journal:  Mol Pharmacol       Date:  2005-05-09       Impact factor: 4.436

4.  Recovery from mu-opioid receptor desensitization after chronic treatment with morphine and methadone.

Authors:  Nidia Quillinan; Elaine K Lau; Michael Virk; Mark von Zastrow; John T Williams
Journal:  J Neurosci       Date:  2011-03-23       Impact factor: 6.167

5.  Two distinct mechanisms mediate acute mu-opioid receptor desensitization in native neurons.

Authors:  Vu C Dang; Ian A Napier; MacDonald J Christie
Journal:  J Neurosci       Date:  2009-03-11       Impact factor: 6.167

Review 6.  Regulated endocytosis of opioid receptors: cellular mechanisms and proposed roles in physiological adaptation to opiate drugs.

Authors:  Mark von Zastrow; Adena Svingos; Helena Haberstock-Debic; Chris Evans
Journal:  Curr Opin Neurobiol       Date:  2003-06       Impact factor: 6.627

7.  mu-Opioid receptors: Ligand-dependent activation of potassium conductance, desensitization, and internalization.

Authors:  Veronica A Alvarez; Seksiri Arttamangkul; Vu Dang; Abdallah Salem; Jennifer L Whistler; Mark Von Zastrow; David K Grandy; John T Williams
Journal:  J Neurosci       Date:  2002-07-01       Impact factor: 6.167

8.  Dynamics of Gαi1 interaction with type 5 adenylate cyclase reveal the molecular basis for high sensitivity of Gi-mediated inhibition of cAMP production.

Authors:  Markus Milde; Andreas Rinne; Frank Wunder; Stefan Engelhardt; Moritz Bünemann
Journal:  Biochem J       Date:  2013-09-15       Impact factor: 3.857

9.  Functional characterization of human variants of the mu-opioid receptor gene.

Authors:  Ajay Ravindranathan; Geoff Joslyn; Margaret Robertson; Marc A Schuckit; Jennifer L Whistler; Raymond L White
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-15       Impact factor: 11.205

10.  Involvement of PKC alpha and G-protein-coupled receptor kinase 2 in agonist-selective desensitization of mu-opioid receptors in mature brain neurons.

Authors:  C P Bailey; S Oldfield; J Llorente; C J Caunt; A G Teschemacher; L Roberts; C A McArdle; F L Smith; W L Dewey; E Kelly; G Henderson
Journal:  Br J Pharmacol       Date:  2009-03-20       Impact factor: 8.739

View more
  3 in total

1.  Themed section.

Authors:  M J Christie; M Connor; J R Traynor
Journal:  Br J Pharmacol       Date:  2015-01       Impact factor: 8.739

Review 2.  Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human μ-opioid receptor (OPRM1).

Authors:  Alisa Knapman; Mark Connor
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

3.  A Novel G Protein-Biased Agonist at the δ Opioid Receptor with Analgesic Efficacy in Models of Chronic Pain.

Authors:  Alexandra E Conibear; Junaid Asghar; Rob Hill; Graeme Henderson; Eva Borbely; Valeria Tekus; Zsuzsanna Helyes; Josephine Palandri; Chris Bailey; Ingemar Starke; Bengt von Mentzer; David Kendall; Eamonn Kelly
Journal:  J Pharmacol Exp Ther       Date:  2019-10-08       Impact factor: 4.030

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.